Derivation Web

source_f538775cccdc4789

by researka:v2 · 2026-06-16 20:42:09.596828+04:00

{"contradictions": ["The conclusion is that NAD+ biomarker effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "Mechanistically, the rationale for NAD+ interventions rests on the well-documented decline of nicotinamide adenine dinucleotide pools with age in multiple tissues, a decline that has been proposed to contribute to mitochondrial dysfunction, impaired stress responses, and the accumulation of senescent cells. The NAD+ precursor family includes nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, and niacin, each of which feeds into the salvage or Preiss–Handler pathways at different points and with different pharmacokinetic signatures. Because several of these molecules are sold as dietary supplements, NAD+ interventions have entered widespread consumer use ahead of definitive clinical evidence, a pattern that complicates the interpretation of observational data. Regulatory pathways have so far treated most NAD+ precursors as foods rather than drugs, and the threshold at which dosing, indication, or formulation should trigger pharmaceutical-grade evaluation appears to be evolving. The combination of mechanistic plausibility and easy over-the-counter access has made NAD+ a particularly important test case for the geroscience hypothesis.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Two clinical RCTs in the curated corpus provide the principal cardiometabolic evidence on NAD+ precursor supplementation. Martens 2018 was a randomized, placebo-controlled, crossover clinical trial of nicotinamide riboside (NR) supplementation at 500 mg twice daily in healthy middle-aged and older adults, with chronic tolerability and NAD+ elevation as the principal endpoints. Both studies are categorized in the curated corpus as indirect with respect to the broader anti-aging framing but direct with respect to cardiometabolic and biomarker physiology, providing the empirical anchor for this outcome class.", "Within-corpus tensions in the cardiometabolic class are limited but informative. Directness is rated indirect in both Katayoshi 2023 and Martens 2018 relative to a hard clinical-event anti-aging endpoint, which constrains inference: the p-values reported above describe physiologic and biomarker change, not event reduction. Effect direction in Martens 2018 is recorded as unclear in the curated matrix even though the contrast-level p-values are conventionally significant, reflecting the chronic-tolerability framing of the trial rather than a null primary endpoint. Read together, the two sources converge on tolerability and biomarker feasibility while leaving the clinical-event translation unresolved.", "The synthesis therefore surfaces a definitional tension rather than a numerical one: longevity-class and contextual-other-class evidence both invoke NAD as a label but operationalise it in incompatible ways, and resolving the tension would require the corpus to disambiguate the acronym at intake.", "In animal/preclinical evidence, quantitatively, the trials reported mixed findings with respect to muscle function endpoints, as summarized in the evidence synthesis. Elhassan 2019, however, identified statistically significant enhancements in NAD metabolome signatures and transcriptional anti-inflammatory responses (e.g., P < 0.001, P = 0.004), though these did not translate into measurable functional gains in muscle performance (P = 0.22, P = 0.31).", "Mechanistically, the disconnect between NAD metabolome augmentation and functional muscle outcomes may reflect the temporal and dose-dependent nature of NAD pathway activation, as well as the heterogeneity of the enrolled populations. Elhassan et al. 2019 demonstrated that NR supplementation increased intramuscular NAD+ levels and upregulated genes associated with oxidative phosphorylation and anti-inflammatory pathways, suggesting a plausible substrate for functional improvement. However, the absence of concurrent gains in muscle performance in Connell 2021 and Yu 2025 implies that NAD augmentation alone may be insufficient to reverse sarcopenic or disease-related declines without additional anabolic or exercise stimuli. Preclinical models consistently show that NAD+ precursors enhance mitochondrial biogenesis and muscle endurance, but these findings have not been consistently replicated in human RCTs, highlighting a translational gap.", "Additional corpus sources included animal/preclinical evidence; within the corpus, the most notable tension arises from Elhassan 2019’s mechanistic successes versus the null functional findings in Connell 2021 and Yu 2025. While Elhassan et al. 2019 reported robust increases in NAD metabolome signatures and transcriptional changes (e.g., P < 0.001), these biochemical effects did not translate to measurable improvements in muscle function metrics, contrasting with the study’s stated thesis of functional augmentation. Conversely, Connell 2021’s trial, which employed a multi-precursor approach over 12 weeks, reported uniformly non-significant p-values across mitochondrial and muscle function outcomes, further underscoring the lack of functional benefit despite theoretical mechanistic plausibility. These discrepancies suggest that the boundary conditions for NAD supplementation—including dose, duration, and baseline NAD status—remain poorly defined in human populations."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "6c682498-cd30-4027-b53a-3d43bbb7eec1", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 24, "included": 24, "included_or_retained": 24, "screened": 24, "wording": "24 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "6c682498-cd30-4027-b53a-3d43bbb7eec1",
  "researka_submission_id": "4d9c51aa-0f45-4731-80e5-fb3c5e636878",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/6c682498-cd30-4027-b53a-3d43bbb7eec1/sidecars/contradiction_map.json"
}